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Protein stabilityProtein kinase C (PKC) signaling regulates osteoblast differentiation, but little is known about its downstream
effectors. We examined the effect of modulating PKC activity on osteogenic transcription factors and found
that the protein level of Msx2 is affected. Msx2 is induced by osteogenic signals such as BMPs and it plays
critical roles in bone formation and osteoblast differentiation. Here, we examined the role of PKC signaling
in regulating the function of Msx2. We found that the inhibition of PKC signaling enhances osteogenic differ-
entiation in BMP2-stimulated C2C12 cells. Treatment with inhibitors of PKC activity or overexpression of
kinase-defective (KD), dominant-negative mutant PKC isoforms strongly reduced the level of Msx2 protein.
Several PKC isoforms (α, β, δ, and ζ) interacted with Msx2, and PKCβ phosphorylated Msx2 at Thr135 and
Thr141. Msx2 repressed the transcriptional activity of the osteogenic transcription factor Runx2, and this re-
pression was relieved by inhibition of PKC activity or overexpression of the KD mutant PKC isoforms. In ad-
dition, PKC prolonged the half-life of Msx2 protein. These results suggest that PKC signaling modulates
osteoblast differentiation, at least in part, through the regulation of Msx2.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Protein kinase C (PKC) signaling mediates various cellular func-
tions such as cell proliferation and differentiation. Studies have
shown that PKC signaling also regulates osteoblast differentiation.
PKC proteins are serine/threonine kinases, and the PKC family
consists of 11 isoforms that can be divided into three subgroups:
Ca2+-dependent conventional PKCs (α, β1, β2, γ), diacylglycerol
(DAG)-dependent novel PKCs (δ, ε, η, θ), and Ca2+/DAG-independent
atypical PKCs (λ/ι and ζ). Several PKC isoforms are expressed during
the osteogenic differentiation of MC3T3-E1 pre-osteoblastic cells and
they play distinct roles [1]. PKCs mediate the signaling of various osteo-
genic regulators such as parathyroid hormone (PTH), FGFs, BMPs,
oxysterol and estrogen [2–4]. In rat and human osteoblast-like cell
lines, PKC signaling is necessary for PTH-induced cell proliferation and
activation of ERKs, and it can induce the transcription of Osteocalcin
[5–7]. PKC β2, δ and θ have been reported to enhance BMP4-induced
osteogenic differentiation [8]. However, the function of PKCα is contro-
versial in that PKCα is necessary for bFGF-induced bone formation yet it+82 2 3277 2385.
+82 62 530 2949.
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rights reserved.suppresses the osteogenic differentiation of rat primary osteoblasts
[9,10]. Although studies have established that PKC signaling regulates
bone formation, the downstream effectors of PKC signaling during this
process are largely unknown. PKC signaling regulates the expression
of the osteogenic transcription factor Runx2, and it regulates the activity
of Runx2 via phosphorylation upon FGF stimulation or mechanical
stress [11,12].
We examined the effect of modulating PKC activity on the levels of
several osteogenic transcription factors and found that PKC activity
modulates the level of Msx2 protein. Msx2 (msh homeobox homolog
2) belongs to a family of transcription factors that consist of three verte-
brate homologs of Drosophila muscle segment homeobox (msh). Msx2
plays critical roles in bone development. Individuals with a gain-
of-function mutation in theMSX2 gene suffer Boston-type craniosynos-
tosis, characterized by premature fusion of skull bones and abnormali-
ties in certain craniofacial bones [13]. In addition, haploinsufﬁciency of
the MSX2 gene in human causes defects in skull ossiﬁcation [14].
Msx2-null mice also exhibit defects in endochondral bone formation
due to defects in the proliferation of osteoprogenitors [15]. However,
the precise function of Msx2 is still controversial. Msx2 promotes the
osteogenic differentiation of skeletal progenitors by reducing Dkk1
expression and subsequently enhancingWnt signaling [16]. In primary
aortic myoﬁbroblasts, Msx2 inhibits adipogenic differentiation through
the interaction with C/EBPα and subsequent reduction of PPARγ
expression, and it promotes BMP-induced osteogenic differentiation
1226 H.M. Jeong et al. / Biochimica et Biophysica Acta 1823 (2012) 1225–1232[17]. These reports suggest that Msx2 has positive roles in osteogenic
differentiation. However, other studies have shown that Msx2 can
inhibit osteogenic differentiation. Msx2 represses the expression of
bone markers such as Alkaline phosphatase and Osteocalcin [18–21],
and it inhibits the function of osteogenic transcription factors such as
Runx2, Dlx3 and Dlx5 [22,23]. In addition, Msx2 inhibits calvarial
osteoblast differentiation in vivo and the mineralization of osteoblasts
in vitro, whereas it stimulates osteoprogenitor proliferation at the oste-
ogenic front of the suture [24]. Although studies have established that
Msx2 plays critical roles during bone development, the precise control
mechanisms by upstream regulators of Msx2 are largely unknown.
Both PKC signaling and Msx2 play essential roles in bone forma-
tion, yet the potential interaction and regulation between them
have not been investigated. In this study, we examined the regulation
of Msx2 function by PKC signaling. We found evidence that PKC acti-
vation represses BMP2-induced osteoblast differentiation while it in-
creases the protein stability of Msx2. PKC inhibition relieved the
suppression of Runx2 transcriptional activity by Msx2. We also
found that various PKC isoforms interact with Msx2, and PKCβ can
phosphorylate Msx2 at Thr135 and Thr141. Furthermore, mutations
at Thr135 of Msx2 affected Msx2 protein stability. Finally, mutations
in the putative PKC phosphorylation target sites on Mxs2 abolished
the ability of PKC signaling to modulate the repressive ability of
Msx2 on Runx2 transcriptional activity. These results suggest that
PKC signaling enhances the activity of Msx2 post-translationally and
inhibits osteogenic differentiation, at least in part, through Msx2.
2. Materials and methods
2.1. Cell culture
C2C12 mouse myoblast and 293 human embryonic kidney cell
lines were maintained at 37 °C, 5% CO2 in DMEM supplemented
with fetal bovine serum (20% or 10% respectively), antibiotics, and
antimycotics. All culture media and supplements were purchased
from Invitrogen.
2.2. Plasmids, antibodies and reagents
C-terminal HA-tagged human PKC α, β1, δ, ζ expression plasmids
were obtained from Dr. J.-W. Soh (http://www.pkclab.org). N-terminal
epitope-tagged human Msx2 expression plasmids were constructed in
a CMV promoter-derived mammalian expression vector (pCS4+).
T135A, T135E, and T141A Msx2 mutants were generated by PCR-based
mutagenesis and conﬁrmed by DNA sequencing. ALP-Luc, Cyclin
D1-Luc, and OC-Luc reporter plasmids were generously provided
by Dr. N. Kim (Chonnam National University). Antibodies against
GFP (B-2), Msx2 (M-70) and Myc (9E10) (Santa Cruz Biotechnolo-
gy), HA (12CA5, Roche Applied Science) and α-tubulin (DM1A, Cell
Signaling Technology) were used. Gö6976, Gö6983, MG132 and
PMA were purchased from EMD4Biosciences. Recombinant human
BMP-2 (355-BM) was purchased from R&D Systems.
2.3. RNA preparation and semi-quantitative RT-PCR
Total cellular RNA was prepared using TRIzol reagent (Invitrogen)
according to the manufacturer's instructions. cDNAs were synthe-
sized using SuperScript III First-Strand Synthesis System (Invitrogen).
The following conditions were used for the PCR ampliﬁcation of
cDNA: initial denaturation at 94 °C for 1 min; 28–30 cycles of dena-
turation at 94 °C for 30 s, annealing at a temperature optimized for
each primer pair for 30 s, and extension at 72 °C for 30 s; ﬁnal exten-
sion at 72 °C for 5 min. The following PCR primers were used: ALP,
forward 5′-GAT CAT TCC CAC GTT TTC AC-3′ and reverse 5′-TGC
GGG CTT GTG GGA CCT GC-3′; ColIA, forward 5′-TCT CCA CTC TTC
TAG GTT CCT-3′ and reverse 5′-TTG GGT CAT TTC CAC ATG C-3′;GAPDH, forward 5′-ACC ACA GTC CAT GCC ATC AC-3′ and reverse
5′-TCC ACC ACC CTG TTG CTG TA-3′. GAPDH was used as an internal
control.
2.4. Alkaline phosphatase (ALP) staining
Cells were ﬁxed in 4% paraformaldehyde for 10 min, washed sev-
eral times with PBS and stained with NBT/BCIP solution (Sigma-
Aldrich) for 15 min. All steps were performed at room temperature.
2.5. DNA transfection and reporter assays
Transient transfections were performed using the calcium phos-
phate method or effectene plus (Qiagen). For immunoblotting, GFP
was co-transfected as an internal control for transfection efﬁciency.
For luciferase assays, 293 cells were seeded on 24-well plates the
day before transfection. pCMV-β-Gal plasmid was co-transfected as
an internal control for transfection efﬁciency. Thirty-six hours after
transfection, luciferase activities were measured using Luciferase
Reporter Assay Kit (Promega) and normalized with corresponding
β-galactosidase activities. Each experiment was repeated three
times, and the averages and standard deviations of a representative
experiment are shown.
2.6. Immunoprecipitation and immunoblotting
Cells were lysed in an ice-cold lysis buffer [25 mM Hepes (pH 7.5),
150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 10% glycerol,
25 mM NaF, 1 mM EDTA, 1 mM Na3VO4, 250 μM PMSF, 10 μg/ml
leupeptin, and 10 μg/ml aprotinin]. Lysates were cleared by centrifuga-
tion. For immunoblotting of supernatants,α-tubulinwas used as a load-
ing control. For immunoprecipitation, the supernatants were incubated
with appropriate antibodies and protein A or G-Sepharose beads. Lysate
supernatants or immunoprecipitated proteins were resolved by SDS‐
PAGE and transferred to PVDF membranes. Proteins were visualized
using appropriate primary antibodies, horseradish peroxidase-coupled
secondary antibodies and chemiluminescenceWestern blotting reagent
(GE Healthcare).
2.7. In vitro kinase assay
Myc-Msx2 was transfected into 293 cells and immuno-
precipitated. The immunoprecipitate was incubated for 30 min at
30 °C with or without recombinant active PKCβ protein (PKC β I ki-
nase, Cell Signaling Technology) in a reaction buffer [20 mM Tris⋅Cl
(pH 7.4), 10 mM MgCl2, 50 μM ATP, 10 μCi γ-[32p]-ATP]. Reactions
were terminated by adding SDS-sample buffer and analyzed by
SDS-PAGE and autoradiography.
2.8. Statistical analysis
All experiments were performed with triplicate independent sam-
ples and were repeated at least twice, giving qualitatively identical
results. Results are expressed as mean±standard error of the mean.
Data were analyzed using Student's t-test, with pb0.05 indicating
signiﬁcance.
3. Results
3.1. PKC activity suppresses osteoblast differentiation in vitro
To examine the effects of PKC activity on osteoblast differentia-
tion, we ﬁrst analyzed whether PKC activator or inhibitor modulates
the expression of osteoblast markers in BMP2-stimulated C2C12
cells. The C2C12 mouse myoblast cell line maintains osteogenic po-
tential and its differentiation pathway can be shifted from myoblastic
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pression of two osteoblast markers, Alkaline phosphatase (ALP) and
Collagen type I A (ColIA) (Fig. 1A). PKC activation, with a PKC activator
PMA, signiﬁcantly reduced the BMP2-induced expression of ALP and
ColIA. Conversely, PKC inhibition with Gö6983 further increased the
BMP2-induced marker expression. However, another PKC inhibitor
Gö6976 slightly increased the expression of ALP but did not alter
the expression of ColIA signiﬁcantly. Gö6976 and Gö6983 have differ-
ent speciﬁcities for PKC; Gö6976 inhibits Ca2+-dependent PKC
isoforms (α, β, γ) and PKD, whereas Gö6983 inhibits all PKC isoforms
but does not inhibit PKD [26,27].
Next, we examined whether PKC activity affects the BMP2-induced
expression of ALP protein when assayed by ALP staining. BMP2
increased the ALP staining in a dose-dependent manner (Fig. 1B, top
panel). Treatment with Gö6976 or Gö6983 enhanced the BMP2-
induced increase of ALP staining in a dose-dependent manner (Fig. 1B,
second and third panels). Conversely, treatment with increasing con-
centrations of PMA gradually decreased the BMP2-increased ALP
staining (Fig. 1B, bottom panel). However, this decrease by PMA is not
likely due to a decrease in cell proliferation as PMA treatment did not
decrease the proliferation of C2C12 cells (data not shown, also see
Fig. 6C). We also examined the effect of PKC inhibition on the expres-
sion of a luciferase reporter (ALP-Luc) containing the promoter region
of ALP. BMP2 induced the expression of ALP-Luc in C2C12 cells, and
PKC inhibitors further increased the reporter expression (Fig. 1C).
These results suggest that PKC activity suppresses the BMP2-induced
osteogenic differentiation of C2C12 cells.A
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PKCs may affect osteoblast differentiation by modulating the func-
tion of target proteins. Therefore, we examined the effect of modulat-
ing PKC activity on the levels of several osteogenic transcription
factors and found that PKC activity modulates the level of Msx2 pro-
tein. Inhibition of PKC, either by Gö6976 or Gö6983, decreased the
level of overexpressed Msx2 protein in 293 cells (Fig. 2A). Conversely,
PKC activation increased the level of overexpressed Msx2 protein
(Fig. 2B). We also examined the effect of modulating PKC activity on
the level of endogenous Msx2 protein in C2C12 cells. C2C12 cells
expressed low levels of Msx2, if any at all, under non-differentiating
conditions. BMP2 stimulation increased the level of Msx2, but this in-
crease was abolished upon PKC inhibition (Fig. 2C). Conversely, PKC
activation signiﬁcantly increased the level of Msx2 above that by
BMP2 alone. These results suggest that PKCs modulate the level of
Msx2 protein. Previous studies have reported that Msx2 acts as a neg-
ative transcriptional regulator for osteogenesis at multiple steps [28].
Our results suggest that PKC activity suppresses osteogenic differenti-
ation while increasing the level of Msx2 protein, indicating that PKCs
may suppress osteogenic differentiation by increasing the level and
therefore the osteogenesis-suppressing activity of Msx2.
Next, we examined which PKC isoform is able to affect the level of
Msx2 protein. PKCβ increased the level of overexpressed Msx2, but
PKC α, δ and ζ did not have any signiﬁcant effects (Fig. 2D). A
kinase-defective (KD) mutant form of PKCβ decreased Msx2 protein
level, and PKC α and δ KD mutants also did so but to lesser degreesolIA
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effect. These results suggest that PKCs, particularly the Ca2+-dependent
PKC isoforms, affect the level of Msx2 protein.
3.3. Msx2 interacts with PKCs and is phosphorylated by PKCβ in vitro
PKCs modulate the function of target proteins through direct mod-
iﬁcations or through modulation of the targets' upstream effectors.
Therefore, we examined the possibility of interaction between PKC
isoforms and Msx2 by co-immunoprecipitation of these proteins
expressed in 293 cells. All wild‐type PKC isoforms, we tested, co-
immunoprecipitated with Msx2 (Fig. 3A). However, the KD mutants
of PKC α and β interacted with Msx2 to signiﬁcantly lesser degrees
than their wild-type counterparts.
Given that PKCs interacted with Msx2, we next used in vitro kinase
assays to examine whether PKC phosphorylates Msx2. Recombinant
active PKCβ was used for this assay, as the protein level of Msx2
was affected more by PKCβ than by other PKC isoforms (Fig. 2D).
PKCβ phosphorylated Msx2 (Fig. 3B). Msx2 has two potential PKC
phosphorylation target sites (Thr135 and Thr141). To determine if
PKC phosphorylates Msx2 at these sites, we generated threonine-
to-alanine substitutionmutants (T135A and T141A) ofMsx2 and exam-
ined the phosphorylation of these mutants by PKCβ. Phosphorylation
by PKCβ was greatly reduced for Msx2 mutants when compared to
that of the wild-type Msx2 (Fig. 3B). These results suggest that Thr135
and Thr141 on Msx2 are major, if not the exclusive, phosphorylation
target sites of PKCβ.
3.4. PKC activity prevents Msx2 ubiquitination
PKC activation enhanced and PKC inhibition abolished the BMP2-
induced increase in Msx2 protein levels in C2C12 cells (Fig. 2C). PKC
may modulate Msx2 protein level through the regulation of Msx2
transcription, translation or protein stability. PKC inhibition or activa-
tion did not signiﬁcantly affect the level of Msx2 transcript (Fig. 4A),
indicating that PKC activity likely modulates Msx2 expression at the
protein level rather than the transcription level. A major pathwayfor the modulation of cellular protein levels is the ubiquitin and
proteosome-mediated degradation system, in which proteins are
committed to proteosomal degradation by the ligation of ubiquitin
(Ub) [29,30]. We therefore examined the ubiquitination of Msx2.
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of Ub but was increased in the presence of a proteosome inhibitor
MG132 (Fig. 4B, left panel). Also, the level of ubiquitinated Msx2
was increased upon Ub co-transfection, even when the level of total
Msx2 protein was decreased (Fig. 4B, right panel). These results sug-
gest that the Msx2 protein level can be regulated by the ubiquitin-
proteosome degradation pathway.
We next examined whether PKC activity regulates the protein
stability of Msx2 by analyzing the effect of PKC on the half-life of
Msx2 protein. PKC activation prolonged the half-life of Msx2 in 293
cells (Fig. 4C). Similarly, the half-life of Msx2 protein was increased inthe presence of wild-type PKCβ but signiﬁcantly reduced in the pres-
ence of the PKCβ KD mutant. We also examined the effect of a
phospho-mimetic mutation of Msx2 at Thr135 (T135E, a threonine to
glutamic acid substitution) on the half-life of Msx2 protein. The half-
life of Msx2(T135E) was signiﬁcantly longer than that of wild-type
Msx2 in 293 cells (Fig. 4D).
Finally, we examined the effect of the T135E mutation on the half-
life of Msx2 protein in C2C12 cells. The protein level of wild-type
Msx2 was reduced upon PKC inhibition whereas that of Msx2(T135E)
mutant was not affected (Fig. 4E). These results suggest that the phos-
phorylation of Msx2 by PKC may increase the protein stability of Msx2.
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activity by Msx2
Previous studies have reported that Msx2 can inhibit osteoblast dif-
ferentiation through the repression of Runx2 transcriptional activity
[31]. Therefore we analyzed the effect of PKC activity on this ability of
Msx2. An Osteocalcin promoter luciferase reporter (OC-Luc) contains
Runx2-responsive elements. Runx2 induced the expression of OC-Luc
(Fig. 5A). Msx2 decreased the Runx2-induced expression of OC-Luc,
and PKC inhibitors relieved this suppression in dose-dependent man-
ners. We then examined the effects of overexpressing PKC isoforms
on the ability of Msx2 to suppress the Runx2 transcriptional activity.
Runx2-mediated OC-Luc activation was signiﬁcantly restored by the
KDmutant of PKC β or δ and to a lesser degree by PKCα or ζ KDmutant
(Fig. 5B). These results suggest that the suppressive effect of Msx2 on
Runx2 transcriptional activity can be modulated by PKC.
3.6. Msx2 is associated with osteoprogenitor cell proliferation
Satokata et al. reported that Msx2-null mice exhibit defects in the
proliferation of osteoprogenitors at the osteogenic front during calvarial
morphogenesis [15]. In addition, a recent study suggests that Msx2
increases the proliferation of osteoprogenitors [32]. BMP2 stimulation
increased the expression of the cell cycle control protein Cyclin D1 in
C2C12 cells, and this increase was further enhanced upon Msx2 over-
expression in a dose-dependent manner (Fig. 6A and B). BMP2 also
stimulated the expression of CDK4, the kinase partner of Cyclin D1,
but CDK4 expression was not signiﬁcantly changed with Msx2. To
examine the possible regulation of PKC activity in Msx2-induced cell
cycle change, the expression of a luciferase reporter containing Cyclin
D1 promoter (Cyclin D1-Luc)was analyzed in 293 cells. Msx2 increased
the expression of Cyclin D1-Luc, and this was further enhanced by PKC
activation (Fig. 6C). PKC inhibition reduced Msx2-induced reporter
expression only slightly (Fig. 6C). These results suggest that Msx2 in-
creases the osteoprogenitor proliferation, and PKC activitymay enhance
this function of Msx2. These results also suggest that the decrease of
BMP2-induced ALP staining upon PKC activation (Fig. 1B) is not due
to a decrease in the cell proliferation.
4. Discussion
In this study, we provide evidence that PKC activity stabilizes
BMP2-induced Msx2 protein expression through the phosphoryla-
tion of Msx2, and that PKC activity may suppress BMP2-induced
osteogenic differentiation, at least in part, through the stabilization
of Msx2 and the inhibition of Runx2 transcriptional activity by
Msx2. We also found that PKC activity promotes the osteoprogenitor
proliferation.
Thr135 and Thr141 in Msx2 can be phosphorylated by PKCβ, and
Thr135 is important for regulating the protein stability of Msx2 by
PKCs. Studies suggest that ERK and p38 MAPK pathways are particu-
larly important for the up-regulation of Msx2 in advanced pancreatic
cancer cells [33]. This raises the possibility that protein kinases may
affect the function of Msx2. However, the precise regulation of
Msx2 function by different kinases during osteogenesis remains
unclear. We investigated the ability of various kinases to modulate
Msx2 function, and found that Msx2 is affected more by PKC than
by other kinases (data not shown). Identifying the precise phosphor-
ylation target sites for PKC isoforms on Msx2 and the effect of Msx2
phosphorylation by PKC isoforms on the function of Msx2 in vivo
will further enhance the understanding of the regulatory roles of
PKC isoforms and the function of Msx2 during osteoblast differentia-
tion and bone formation.
A recent study suggested that PKCα suppresses osteogenic differ-
entiation of MC3T3-E1 cells [10]. This conclusion was based on the
facts that treatment with Gö6976 or Gö6983, but not with a PKCβ
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Fig. 6.Msx2 is associated with osteoprogenitor cell proliferation. (A) C2C12 cells were cultured with or without BMP2 (10 ng/ml) for 2 days. (B) C2C12 cells were transfected with
increasing amounts of Msx2 (0.5 and 1 μg) for 24 h. Cells were then cultured as in A. Levels of Cyclin D1 and CDK4 proteins were compared by immunoblotting. (C) 293 cells were
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entiation. We also found that both Gö6976 and Gö6983 enhance
the osteogenic differentiation of C2C12 cells. Gö6976 inhibits only
the Ca2+-dependent PKC isoforms (α, β, γ) and PKD, while Gö6983
inhibits all isoforms of PKC. Our results indicate that, in 293 cells,
both Gö6976 and Gö6983 decrease the level of overexpressed Msx2
protein, and PKC α, β, δ, and ζ all interacted with Msx2. However,
only PKCβ had signiﬁcant effect to the Msx2 protein level. It is possi-
ble that PKC α and β suppress osteoblast differentiation by affecting
the function of distinct target proteins and/or that different osteo-
genic cell lines express distinct PKC isoforms. Therefore identifying
the targets of each PKC isoform will help us understand the precise
roles of PKC isoforms. In addition, the expression/activation patterns
of PKC isoforms and the effects of knockdown of PKC isoforms during
osteoblast differentiation need to be compared.
Studies have indicated thatMsx2 represses the transcriptional activ-
ities of osteogenic transcription factors such as Runx2, Dlx3 and Dlx5
[31,34].We also found thatMsx2 can repress the transcriptional activity
of Runx2, and furthermorewe found that PKC activity canmodulate this
activity of Msx2. Meanwhile, studies suggest that Msx2 promotes the
proliferation of osteoprogenitors. We found that Msx2 increases the
expression of Cyclin D1 protein, a critical regulator of the cell cycle tran-
sition from G1 to S phase. Hu et al. suggested that Msx1 plays a positive
role in osteoblast proliferation via the induction of Cyclin D1 expres-
sion [35]. PKC β1 and β2 regulate the expression of Cyclin D1 in other
mammalian cells [36]. The increased expression of Cyclin D1 signiﬁes
cell-cycle progression and cell proliferation, whereas the decreased
expression of Cyclin D1 is a hallmark of differentiation. Taken together,
the results of our and others suggest thatMsx2 suppresses the differen-
tiation but promotes the proliferation of osteogenic cells. However,
Msx2 mutant mice exhibit defects in bone formation and a reduction
of osteoblasts [15]. It is likely that the phenotypes of Msx2-null mice
are due to the reduction of osteoprogenitor proliferation but not due
to the reduction of osteoblast differentiation per se.
In conclusion, we suggest that the phosphorylation and subsequent
stabilization of Msx2 by PKCβ can prevent osteogenic differentiation,and this suppression of osteogenic differentiation may be due to the
repression of Runx2 transcriptional activity and the simultaneous
promotion of osteoprogenitor proliferation.Acknowledgements
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